ArticleThe EMBO journal2017
Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387.
Article in The EMBO journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- CDK14 regulates the development and repair of lung.Cell death discovery · 2025Article
- Transcriptional control of interferon-stimulated genes.The Journal of biological chemistry · 2024Review
- The crucial regulatory role of type I interferon in inflammatory diseases.Cell & bioscience · 2023Review
- Maternal antibiotic exposure enhances ILC2 activation in neonates via downregulation of IFN1 signaling.Nature communications · 2023Article
- How cancer cells make and respond to interferon-I.Trends in cancer · 2023Review
- Review
- Exposing the Two Contrasting Faces of STAT2 in Inflammation.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2022Review
- The long non-coding RNA LNC_000397 negatively regulates PRRSV replication through induction of interferon-stimulated genes.Virology journal · 2022Article
- Consequences of sex differences in Type I IFN responses for the regulation of antiviral immunity.Frontiers in immunology · 2022Review
- Human Disease Phenotypes Associated with Loss and Gain of Function Mutations in STAT2: Viral Susceptibility and Type I Interferonopathy.Journal of clinical immunology · 2021Review
- FBXW7-mediated stability regulation of signal transducer and activator of transcription 2 in melanoma formation.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Differential Responsiveness of Monocyte and Macrophage Subsets to Interferon.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.Seminars in immunology · 2019Review
- Differential Regulation of Type I and Type III Interferon Signaling.International journal of molecular sciences · 2019Review
- Bclaf1 critically regulates the type I interferon response and is degraded by alphaherpesvirus US3.PLoS pathogens · 2019Article
- Fine-Tuning of Type I Interferon Response by STAT3.Frontiers in immunology · 2019Review
- Molecular cross-talk of IL-6 in tumors and new progress in combined therapy.Thoracic cancer · 2018Review
- Cyclin-dependent kinase activity is required for type I interferon production.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Responses to Cytokines and Interferons that Depend upon JAKs and STATs.Cold Spring Harbor perspectives in biology · 2018Review
- Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387.The EMBO journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The transcription factor ISGF3, comprised of IRF9 and tyrosine-phosphorylated STATs 1 and 2, transmits the signal from the type I interferon receptor to the genome. We have discovered a novel phosphorylation of STAT2 on T387 that negatively regulates this response. In most untreated cell types, the majority of STAT2 is phosphorylated on T387 constitutively. In response to interferon-β, the T387A mutant of STAT2 is much more effective than wild-type STAT2 in mediating the expression of many interferon-stimulated genes, in protecting cells against virus infection, and in inhibiting cell growth. Interferon-β-treated cells expressing wild-type STAT2 contain much less ISGF3 capable of binding to an interferon-stimulated response element than do cells expressing T387A STAT2. T387 lies in a cyclin-dependent kinase (CDK) consensus sequence, and CDK inhibitors decrease T387 phosphorylation. Using CDK inhibitors to reverse the constitutive inhibitory phosphorylation of T387 of U-STAT2 might enhance the efficacy of type I interferons in many different clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.